BioCentury | Sep 14, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

New Therapeutic Targets and Biomarkers: August 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during August 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Aug 9, 2017
Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample, cell culture and mouse studies suggest promoting the expression of CIB2 could help treat ovarian cancer. In patient tissue samples, tumor levels of CIB2 were lower than in matched normal...
BioCentury | May 30, 2016
Financial News

Quest Diagnostics completes private placement of senior notes

Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Diagnostic Date completed: 2016-05-26 Type: Private placement of senior notes Raised: $500 million Underwriters: Goldman Sachs; Mizuho; Wells Fargo; Credit Agricole CIB; Mitsubishi UFJ Financial Group; PNC Capital...
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: Family with sequence similarity 120A (FAM120A); interleukin-13 (IL-13); IL-13 receptor α 2 (IL-13RA2; IL-13R; CD213A2)

Cancer INDICATION: Colon cancer In vitro, mouse and patient sample studies suggest inhibiting FAM120A could help treat colon cancer. In tissue samples from colorectal cancer patients, FAM120A levels were higher in tumors than in adjacent...
BioCentury | Feb 9, 2015
Financial News

Valneva completes rights offering

Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France Business: Antibodies, Infectious Date completed: 2015-02-04 Type: Rights offering Raised: EUR45 million ($51 million) Shares: 18.2 million Price: EUR2.47 Shares after offering: 74.6 million Investor: Existing investors Underwriters: Credit...
BioCentury | Jan 26, 2015
Financial News

LabCorp completes private placement of senior notes

Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Business: Diagnostic Date completed: 2015-01-21 Type: Private placement of senior notes Raised: $2.9 billion Underwriters: BofA Merrill Lynch; Wells Fargo; Credit Suisse; Mitsubishi UFJ Morgan Stanley Securities...
BioCentury | Jan 19, 2015
Financial News

Valneva proposes rights offering

Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France Business: Antibodies, Infectious Date announced: 2015-01-12 Type: Rights offering To be raised: Up to ÿ45 million ($53.2 million) Shares: 18.2 million Price: ÿ2.47 Shares outstanding prior: 56.4 million Investor:...
BioCentury | Sep 30, 2013
Financial News

UCB completes bond

UCB Group (Euronext:UCB), Brussels, Belgium Business: Neurology, Autoimmune, Inflammation Date completed: 9/27/13 Type: Bond Raised: €350 million ($473.4 million) Underwriters: Barclays Capital; CA-CIB; Royal Bank of Scotland; Santander; Mitsubishi UFJ Securities International; DNB Markets; Mizuho;...
BioCentury | Sep 28, 2013
Financial News

UCB raises EUR 350 million in bond deal

UCB Group (Euronext:UCB) raised EUR 350 million ($473.4 million) through the sale of 4.125% senior unsecured bonds due January 2021 to institutional investors in Europe. Barclays; CA-CIB; and the Royal Bank of Scotland were global...
BioCentury | Jul 15, 2013
Financial News

Valneva completes rights offering

Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France Business: Antibodies, Infectious Date completed: 7/4/13 Type: Rights offering Raised: €40.2 million ($52.3 million) Shares: 15.2 million Price: €2.65 Shares after offering: 54.6 million Underwriters: Credit Agricole CIB; Societe...
Items per page:
1 - 10 of 22